-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Gilead made a long-term outlook on its performance prospects
This also means that the company will need to undergo a major transformation in the future
Beyond that, Gilead sees another big payoff coming from the 20 oncology drugs under development
For investors, Gilead will gradually increase the performance of its oncology franchise, making it a third of total revenue
Previously, Gilead has partnered with dozens of biotech companies including Kite and Immunomedics
Reference source:
Reference source:1.
1.
2.
Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030